HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
50 sources retrieved Β· Most recent: April 2026 Β· Index updated 14 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
TP53
tumor protein p53
Chromosome 17 Β· 17p13.1
NCBI Gene: 7157Ensembl: ENSG00000141510.19HGNC: HGNC:11998UniProt: A0A087WT22
11,616PubMed Papers
28Diseases
8Drugs
1,129Pathogenic Variants
FUNCTIONAL ROLE
Hub GeneTranscription FactorTumor Suppressor
RESEARCH IMPACT
Highly StudiedLandmark GeneTrendingVariant-Rich
CLINICAL
Clinical TrialsOMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
intrinsic apoptotic signaling pathway by p53 class mediatorregulation of cell cycleregulation of cell cycle G2/M phase transitionDNA damage responseLi-Fraumeni syndromehepatocellular carcinomahead and neck squamous cell carcinomaHereditary breast cancer
✦AI Summary

TP53 encodes the p53 protein, a critical tumor suppressor and transcription factor that serves as the guardian of genome stability 1. The protein functions as a multifunctional transcription factor that directly regulates expression of approximately 500 genes involved in cell cycle arrest, DNA repair, senescence, autophagy, and apoptosis in response to cellular stress 2. Upon activation by stress stimuli, p53 governs an anti-proliferative transcriptional program that prevents tumorigenesis 1. TP53 mutations occur in approximately 50% of human cancers, making it the most frequently mutated gene in cancer 21. In myeloid neoplasms, TP53 mutations are found in 10-15% of cases and represent one of the most important prognostic factors, with multihit TP53 mutations associated with particularly poor outcomes 3. Most cancer-causing mutations are missense substitutions within the DNA-binding domain, with hotspot mutations at residues R175, Y220, G245, R248, R273, or R282 representing ~35% of all missense mutations 4. Germline TP53 mutations cause Li-Fraumeni syndrome, characterized by predisposition to multiple cancer types with significant clinical heterogeneity even within families carrying identical mutations 5. The protein's diverse roles extend beyond cancer to fertility, aging, longevity, and environmental adaptation 6.

Sources cited
1
p53 is activated by stress stimuli and governs anti-proliferative transcriptional programs
PMID: 28886379
2
TP53 mutations found in ~50% of cancers and regulates ~500 genes involved in tumor suppression
PMID: 35332311
3
TP53 mutations in 10-15% of myeloid neoplasms with multihit mutations having poor prognosis
PMID: 40729726
4
Hotspot mutations at specific residues represent ~35% of missense mutations in myeloid diseases
PMID: 39644062
5
Germline TP53 mutations cause Li-Fraumeni syndrome with clinical heterogeneity
PMID: 31691207
6
TP53 roles extend to fertility, aging, longevity, and environmental adaptation
PMID: 36766853
Disease Associationsβ“˜28
Li-Fraumeni syndromeOpen Targets
0.88Strong
hepatocellular carcinomaOpen Targets
0.80Strong
head and neck squamous cell carcinomaOpen Targets
0.78Strong
Hereditary breast cancerOpen Targets
0.74Strong
hereditary breast carcinomaOpen Targets
0.74Strong
colorectal cancerOpen Targets
0.73Strong
lung adenocarcinomaOpen Targets
0.73Strong
esophageal cancerOpen Targets
0.73Strong
choroid plexus papillomaOpen Targets
0.72Strong
acute myeloid leukemiaOpen Targets
0.72Strong
bone marrow failure syndromeOpen Targets
0.72Strong
bone osteosarcomaOpen Targets
0.71Strong
breast adenocarcinomaOpen Targets
0.71Strong
nasopharyngeal carcinomaOpen Targets
0.70Moderate
urinary bladder cancerOpen Targets
0.69Moderate
familial pancreatic carcinomaOpen Targets
0.69Moderate
colorectal adenocarcinomaOpen Targets
0.69Moderate
basal cell carcinoma, susceptibility to, 7Open Targets
0.69Moderate
pancreatic carcinomaOpen Targets
0.69Moderate
osteosarcomaOpen Targets
0.69Moderate
Adrenocortical carcinomaUniProt
Basal cell carcinoma 7UniProt
Bone marrow failure syndrome 5UniProt
Esophageal cancerUniProt
Li-Fraumeni syndromeUniProt
Lung cancerUniProt
Papilloma of choroid plexusUniProt
Squamous cell carcinoma of the head and neckUniProt
Pathogenic Variants1,129
NM_000546.6(TP53):c.1031T>G (p.Leu344Arg)Likely pathogenic
Li-Fraumeni syndrome|Hereditary cancer-predisposing syndrome
β˜…β˜…β˜…β˜†2026β†’ Residue 344
NM_000546.6(TP53):c.581T>G (p.Leu194Arg)Pathogenic
Colorectal cancer|Li-Fraumeni syndrome|Hereditary cancer-predisposing syndrome|Ovarian neoplasm|Li-Fraumeni syndrome 1|Hereditary breast ovarian cancer syndrome|TP53-related disorder
β˜…β˜…β˜…β˜†2026β†’ Residue 194
NM_000546.6(TP53):c.379T>A (p.Ser127Thr)Likely pathogenic
Hereditary cancer-predisposing syndrome|Li-Fraumeni syndrome|Li-Fraumeni syndrome 1|Diffuse midline glioma, H3 K27M-mutant
β˜…β˜…β˜…β˜†2026β†’ Residue 127
NM_000546.6(TP53):c.800G>A (p.Arg267Gln)Likely pathogenic
Hereditary cancer-predisposing syndrome|Li-Fraumeni syndrome|not provided|Li-Fraumeni syndrome 1|Malignant tumor of breast|not specified|Adrenocortical carcinoma, hereditary|Neoplasm
β˜…β˜…β˜…β˜†2026β†’ Residue 267
NM_000546.6(TP53):c.761T>C (p.Ile254Thr)Pathogenic
Hereditary cancer-predisposing syndrome|Acute myeloid leukemia|Li-Fraumeni syndrome|Li-Fraumeni syndrome 1
β˜…β˜…β˜…β˜†2026β†’ Residue 254
NM_000546.6(TP53):c.332T>G (p.Leu111Arg)Pathogenic
Li-Fraumeni syndrome
β˜…β˜…β˜…β˜†2026β†’ Residue 111
NM_000546.6(TP53):c.380C>A (p.Ser127Tyr)Pathogenic
Li-Fraumeni syndrome|Li-Fraumeni syndrome 1|Hereditary cancer-predisposing syndrome
β˜…β˜…β˜…β˜†2026β†’ Residue 127
NM_000546.6(TP53):c.-29+1G>TLikely pathogenic
Li-Fraumeni syndrome
β˜…β˜…β˜…β˜†2025
NM_000546.6(TP53):c.322_332delinsATTCA (p.Gly108_Leu111delinsIleGln)Likely pathogenic
Li-Fraumeni syndrome
β˜…β˜…β˜…β˜†2025β†’ Residue 108
NM_000546.6(TP53):c.332T>C (p.Leu111Pro)Pathogenic
Ovarian neoplasm|not provided|Li-Fraumeni syndrome|Li-Fraumeni syndrome 1|Hereditary cancer-predisposing syndrome
β˜…β˜…β˜…β˜†2025β†’ Residue 111
NM_000546.6(TP53):c.375+5G>ALikely pathogenic
Hereditary cancer-predisposing syndrome|Ovarian neoplasm|not provided|Li-Fraumeni syndrome|Li-Fraumeni syndrome 1|Hereditary breast ovarian cancer syndrome|Uterine carcinosarcoma|Osteosarcoma
β˜…β˜…β˜…β˜†2025
NM_000546.6(TP53):c.318C>G (p.Ser106Arg)Pathogenic
not specified|Li-Fraumeni syndrome|not provided
β˜…β˜…β˜…β˜†2025β†’ Residue 106
NM_000546.6(TP53):c.541C>T (p.Arg181Cys)Likely pathogenic
Hereditary cancer-predisposing syndrome|Li-Fraumeni syndrome|not provided|Adrenocortical carcinoma, hereditary|Familial cancer of breast|Neoplasm|Li-Fraumeni syndrome 1|Colorectal cancer
β˜…β˜…β˜…β˜†2025β†’ Residue 181
NM_000546.6(TP53):c.829T>G (p.Cys277Gly)Likely pathogenic
Li-Fraumeni syndrome|Hereditary cancer-predisposing syndrome
β˜…β˜…β˜…β˜†2025β†’ Residue 277
NM_000546.6(TP53):c.473G>C (p.Arg158Pro)Pathogenic
not provided|Li-Fraumeni syndrome|Squamous cell carcinoma of the head and neck|Hereditary cancer-predisposing syndrome|Li-Fraumeni syndrome 1|IDH-wildtype glioblastoma|Neoplasm
β˜…β˜…β˜…β˜†2025β†’ Residue 158
NM_000546.6(TP53):c.473G>T (p.Arg158Leu)Pathogenic
Li-Fraumeni syndrome|not provided|Li-Fraumeni syndrome 1|Hereditary cancer-predisposing syndrome|Diffuse midline glioma, H3 K27M-mutant
β˜…β˜…β˜…β˜†2025β†’ Residue 158
NM_000546.6(TP53):c.754_762del (p.Leu252_Ile254del)Pathogenic
Li-Fraumeni syndrome|Hereditary cancer-predisposing syndrome|Li-Fraumeni syndrome 1|Neoplasm|not provided
β˜…β˜…β˜…β˜†2025β†’ Residue 252
NM_000546.6(TP53):c.487T>C (p.Tyr163His)Pathogenic
Hereditary cancer-predisposing syndrome|Li-Fraumeni syndrome|Li-Fraumeni syndrome 1|Adrenocortical carcinoma, hereditary
β˜…β˜…β˜…β˜†2025β†’ Residue 163
NM_000546.6(TP53):c.1179dup (p.Ter394LeuextTer?)Likely pathogenic
Hereditary cancer-predisposing syndrome|Li-Fraumeni syndrome
β˜…β˜…β˜…β˜†2025β†’ Residue 394
NM_000546.6(TP53):c.761T>A (p.Ile254Asn)Pathogenic
Li-Fraumeni syndrome|Li-Fraumeni syndrome 1|Hereditary cancer-predisposing syndrome
β˜…β˜…β˜…β˜†2025β†’ Residue 254
View on ClinVar β†—
Drug Targets8
ALRIZOMADLINPhase II
Tumour suppressor p53/oncoprotein Mdm2 inhibitor
CENERSENPhase II
p53 mRNA antisense inhibitor
acute myeloid leukemia by FAB classification
CONTUSUGENE LADENOVECPhase III
Cellular tumor antigen p53 exogenous gene
tongue neoplasm
EPRENETAPOPTPhase III
Cellular tumor antigen p53 stabiliser
myelodysplastic syndrome
IDASANUTLINPhase III
Tumour suppressor p53/oncoprotein Mdm2 inhibitor
acute myeloid leukemia by FAB classification
NAVTEMADLINPhase II/III
Tumour suppressor p53/oncoprotein Mdm2 inhibitor
endometrial cancer
SIREMADLINPhase II
Tumour suppressor p53/oncoprotein Mdm2 inhibitor
neoplasm
TEPRASIRANPhase III
p53 mRNA RNAi inhibitor
Related Genes
BNIP3LProtein interaction100%CCNG1Protein interaction100%CSNK1A1Protein interaction100%CSNK2A1Protein interaction100%DNMT1Protein interaction100%FOXO3Protein interaction100%
Tissue Expression6 tissues
Ovary
100%
Brain
83%
Lung
70%
Bone Marrow
66%
Liver
65%
Heart
41%
Gene Interaction Network
Click a node to explore
TP53BNIP3LCCNG1CSNK1A1CSNK2A1DNMT1FOXO3
PROTEIN STRUCTURE
Preparing viewer…
PDB9C5S Β· 1.01 Γ… Β· X-ray
View on RCSB β†—
Constraintβ“˜
LOEUFβ“˜
0.45Moderately Constrained
pLIβ“˜
1.00Intolerant
Observed/Expected LoF0.28 [0.18–0.45]
RankingsWhere TP53 stands among ~20K protein-coding genes
  • #1of 20,598
    Most Researched11,616 Β· top 1%
  • #25of 5,498
    Most Pathogenic Variants1,129 Β· top 1%
  • #2,496of 17,882
    Most Constrained (LOEUF)0.45 Β· top quartile
Genes detectedTP53
Sources retrieved50 papers
Response timeβ€”
πŸ“„ Sources
50β–Ό
1
The Role of
PMID: 36766853
Cells Β· 2023
1.00
2
TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data.
PMID: 27328919
Hum Mutat Β· 2016
0.90
3
NFIA-ETO2, TP53, and erythroid leukemogenesis.
PMID: 37140954
Blood Β· 2023
0.84
4
Putting p53 in Context.
PMID: 28886379
Cell Β· 2017
0.80
5
Phagocytosing with TP53 and extracellular vesicles.
PMID: 35737407
Blood Β· 2022
0.78